MedPath

Reducing costs of surveillance of patients with non-muscle invasive bladder cancer.

Recruiting
Conditions
Non-muscle invasive bladder cancer
superficial bladder cancer
10038588
10004994
Registration Number
NL-OMON44747
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
435
Inclusion Criteria

1) (Previous) primary NMIBC
2) Currently under surveillance for possible recurrent disease
3) Monitored by the urology patient archives in the participating hospitals

Exclusion Criteria

1) Patients upgraded at reTUR to MIBC
2) Patients presenting with MIBC
3) Patients below 21 years of age. ;After the initial TUR, a second TUR (reTUR) is recommended for patients with pT1 tumors. This is to establish whether resection was radical and when there is remaining tumor whether the tumor is muscle-invasive. In the latter case these patients will be excluded because they do not belong to the NMIBC category

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>- 15% more recurrences detected in the maximal care arm in patients in the<br /><br>low/intermediate risk group.<br /><br>- Proof that in the optimal care arm (intended to be the future follow-up<br /><br>procedure) is safe regarding detected versus missed recurrences.<br /><br>- Calculation of % of cystoscopies that would be unnecessary in the future.<br /><br>- Cost-effectiveness of this strategy.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>- 15% more recurrences detected in patients with a primary high-risk tumor.<br /><br>- Indication that these are of lower stage.<br /><br>- Cost-effectiveness.</p><br>
© Copyright 2025. All Rights Reserved by MedPath